Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 444 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: heparin Clear all
Completed No phase listed Observational

Emulation of the RECORD3 Trial Using Healthcare Claims Data

NCT07599384
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
149,248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 5, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Not applicable Interventional

The Effects of MAP and EtCO2 on Venous Sinus Pressures

NCT03867461
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Venous Sinus Stenting, Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range), Adjustment to Mean Arterial Pressure (100-110 mmHg range), Adjustment to Mean Arterial Pressure (60-80 mmHg range), Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Not applicable Interventional

Comparison of Apixaban Versus Enoxaparin

NCT06243510
View directory record Official record
Conditions
Bladder Cancer
Interventions
apixaban, enoxaparin
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 1 Interventional

Treatment for Blood Clots in the Veins of the Legs

NCT00001713
View directory record Official record
Conditions
Embolism, Thrombophlebitis
Interventions
Recombinant Tissue Plasminogen Activator, Heparin, Warfarin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 5, 2026, 3:47 PM EDT
Recruiting Phase 4 Interventional

Apixaban or Enoxaparin After Head and Neck Cancer Surgery

NCT07189897
View directory record Official record
Conditions
Venous Thromboembolism, Head and Neck Cancer
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Kiranya Arnold
Other
Eligibility
18 Years to 89 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Understanding "Heparin Resistance" in Cardiac Surgery

NCT01598883
View directory record Official record
Conditions
Cardiopulmonary Bypass, Altered Heparin Response
Interventions
Heparin, ATryn
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 5, 2026, 3:47 PM EDT
Not listed Phase 3 Interventional

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

NCT00628680
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
AAT-023 solution (Zuragen), Heparin
Device · Drug
Lead sponsor
Ash Access Technology
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
22
States / cities
Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 5, 2026, 3:47 PM EDT
Terminated No phase listed Observational

Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

NCT04895553
View directory record Official record
Conditions
Glioma, Malignant
Interventions
Observation of ICH and VTE
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Sacramento, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 4 Interventional

FREEDOM COVID-19 Anticoagulation Strategy

NCT04512079
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Enoxaparin, Apixaban
Drug
Lead sponsor
Valentin Fuster
Other
Eligibility
18 Years and older
Enrollment
3,460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 5, 2026, 3:47 PM EDT
Recruiting Not applicable Interventional

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

NCT03728166
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Electronic alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 5, 2026, 3:47 PM EDT
Not listed Phase 4 Interventional

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

NCT02342444
View directory record Official record
Conditions
Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
Interventions
Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
15 Years to 100 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Sep 5, 2026, 3:47 PM EDT
Completed No phase listed Observational

Evaluation of the Heparin Binding Protein Levels in Sepsis

NCT02533011
View directory record Official record
Conditions
Sepsis, Infection, Septic Shock
Interventions
HBP lab test
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
1,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 5, 2026, 3:47 PM EDT
Terminated Phase 4 Interventional Results available

Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion

NCT01246011
View directory record Official record
Conditions
Coronary Artery Bypass Graft Surgery, Presence of Heparin/Platelet Factor 4 Antibody
Interventions
Argatroban and warfarin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 5, 2026, 3:47 PM EDT
Terminated Phase 2 Interventional Results available

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

NCT02591199
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
URG101, Placebo, Lidocaine, Heparin
Drug
Lead sponsor
Urigen
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Escondido, California • San Diego, California • Cartersville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 2 Interventional Results available

t-PA Prophylaxis to Prevent Catheter-associated Thrombosis and Infection

NCT03672006
View directory record Official record
Conditions
Central Venous Catheter Thrombosis, Central Venous Catheter Associated Bloodstream Infection
Interventions
alteplase (recombinant t-PA), Heparin
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Not applicable Interventional Results available

Heparin and the Reduction of Thrombosis (HART) Trial

NCT00779558
View directory record Official record
Conditions
Thrombosis
Interventions
Heparin sulfate infusion at 10 units/kg/hour, Placebo infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 5, 2026, 3:47 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Bladder instillation WITH triamcinolone acetonide, Bladder instillation WITHOUT triamcinolone acetonide
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 5, 2026, 3:47 PM EDT